MHLW Designates Tacrolimus And Infiximab Orphan Drugs
This article was originally published in PharmAsia News
The First Division of the Pharmaceutical and Food Sanitation Council of the Ministry of Health, Labor and Welfare May 26 designated Atellas' tacrolimus monohydrate and Remicade orphan drugs. Tacrolimus is applied to treat myasthenia gravis patients that have not received a thymectomy, and in combination for patients showing effects with steroids. Tacrolimus is now in PhaseIII trials in Japan. There are an estimated 15,000 to 20,000 MG patients in Japan. Remicade (infliximab) is applied to treat ankylosing spondylitis. An anti-TNF drug, infliximab is now in open clinical trials. Patients with AS in Japan are numbered in several thousands. Formal designations are estimated to be within a month. (Click here for more - Japanese language
You may also be interested in...
The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.
Device financing totaled $1.4bn during the first quarter of 2020. Merger and acquisition activity reached $714.5m, with only two transactions hitting the six-figure mark. Financings by diagnostics/research players totaled $985m and just six companies were acquired, four of which together were valued at $11.6bn, most coming from Thermo Fisher Scientific’s $11.5bn buy of fellow public life sciences company Qiagen NV.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.